- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.05 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x FDA: DIHYDROFLAVINE-ADENINE DINUCLEOTIDE(Non-covalent)
- 7 x UDP: URIDINE-5'-DIPHOSPHATE(Non-covalent)
UDP.2: 11 residues within 4Å:- Chain A: R.94, Y.107, F.161, M.162, Y.165, N.166, W.170, W.181, L.182, Y.456
- Ligands: EDO.10
6 PLIP interactions:6 interactions with chain A- Hydrogen bonds: A:R.94, A:Y.107, A:Y.107, A:N.166, A:N.166, A:Y.456
UDP.3: 6 residues within 4Å:- Chain A: K.291, L.293, F.294, Y.295, S.380, S.381
6 PLIP interactions:6 interactions with chain A- Hydrogen bonds: A:L.293, A:Y.295, A:Y.295, A:S.381
- Water bridges: A:S.297, A:S.297
UDP.16: 11 residues within 4Å:- Chain B: R.94, Y.107, F.161, M.162, Y.165, N.166, W.170, W.181, L.182, Y.456
- Ligands: EDO.26
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:N.166, B:N.166, B:Y.456, B:Y.456
UDP.17: 6 residues within 4Å:- Chain B: K.291, L.293, F.294, Y.295, S.380, S.381
8 PLIP interactions:8 interactions with chain B- Hydrogen bonds: B:L.293, B:Y.295, B:Y.295, B:S.381
- Water bridges: B:K.291, B:L.293, B:E.379
- pi-Stacking: B:Y.295
UDP.32: 11 residues within 4Å:- Chain C: R.94, Y.107, M.162, Y.165, N.166, W.170, W.181, L.182, Y.456
- Ligands: EDO.39, EDO.40
5 PLIP interactions:5 interactions with chain C- Hydrogen bonds: C:R.94, C:Y.107, C:N.166, C:N.166, C:Y.456
UDP.33: 6 residues within 4Å:- Chain C: K.291, L.293, F.294, Y.295, S.380, S.381
5 PLIP interactions:5 interactions with chain C- Hydrogen bonds: C:L.293, C:Y.295, C:Y.295, C:S.381
- Water bridges: C:S.297
UDP.48: 11 residues within 4Å:- Chain D: R.94, Y.107, F.161, M.162, Y.165, N.166, W.170, W.181, L.182, Y.456
- Ligands: EDO.54
4 PLIP interactions:4 interactions with chain D- Hydrogen bonds: D:N.166, D:N.166, D:Y.456, D:Y.456
- 18 x SO4: SULFATE ION(Non-functional Binders)
SO4.4: 4 residues within 4Å:- Chain A: P.310, E.311, R.312, K.405
Ligand excluded by PLIPSO4.5: 4 residues within 4Å:- Chain A: P.84, K.85, E.86, D.87
Ligand excluded by PLIPSO4.6: 2 residues within 4Å:- Chain A: K.73, R.499
Ligand excluded by PLIPSO4.7: 4 residues within 4Å:- Chain A: V.385, N.386, Q.387, E.388
Ligand excluded by PLIPSO4.8: 5 residues within 4Å:- Chain A: L.354, P.360, Q.361, S.362, E.409
Ligand excluded by PLIPSO4.18: 4 residues within 4Å:- Chain B: P.310, E.311, R.312, K.405
Ligand excluded by PLIPSO4.19: 3 residues within 4Å:- Chain B: N.43, D.53, R.416
Ligand excluded by PLIPSO4.20: 2 residues within 4Å:- Chain B: K.73, R.499
Ligand excluded by PLIPSO4.21: 3 residues within 4Å:- Chain B: P.84, K.85, E.86
Ligand excluded by PLIPSO4.22: 3 residues within 4Å:- Chain B: N.386, T.389, D.393
Ligand excluded by PLIPSO4.34: 4 residues within 4Å:- Chain C: P.310, E.311, R.312, K.405
Ligand excluded by PLIPSO4.35: 2 residues within 4Å:- Chain C: T.155, R.163
Ligand excluded by PLIPSO4.36: 2 residues within 4Å:- Chain C: P.117, K.118
Ligand excluded by PLIPSO4.37: 2 residues within 4Å:- Chain C: K.73, R.499
Ligand excluded by PLIPSO4.49: 4 residues within 4Å:- Chain D: P.310, E.311, R.312, K.405
Ligand excluded by PLIPSO4.50: 2 residues within 4Å:- Chain D: P.117, K.118
Ligand excluded by PLIPSO4.51: 2 residues within 4Å:- Chain D: T.155, R.163
Ligand excluded by PLIPSO4.52: 3 residues within 4Å:- Chain D: K.73, T.496, R.499
Ligand excluded by PLIP- 28 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.9: 3 residues within 4Å:- Chain A: W.446, N.474
- Chain C: E.497
Ligand excluded by PLIPEDO.10: 6 residues within 4Å:- Chain A: Y.165, V.169, R.330, Y.422, Y.456
- Ligands: UDP.2
Ligand excluded by PLIPEDO.11: 3 residues within 4Å:- Chain A: R.306, D.408, E.409
Ligand excluded by PLIPEDO.12: 5 residues within 4Å:- Chain A: I.68, F.69, S.70, T.212, F.213
Ligand excluded by PLIPEDO.13: 6 residues within 4Å:- Chain A: G.65, H.66, V.67, W.318, R.330
- Ligands: FDA.1
Ligand excluded by PLIPEDO.14: 6 residues within 4Å:- Chain A: W.181, L.182, G.183, P.487, D.488, N.491
Ligand excluded by PLIPEDO.23: 4 residues within 4Å:- Chain B: P.117, E.119
- Ligands: EDO.24, EDO.27
Ligand excluded by PLIPEDO.24: 1 residues within 4Å:- Ligands: EDO.23
Ligand excluded by PLIPEDO.25: 3 residues within 4Å:- Chain B: W.446, N.474
- Chain D: E.497
Ligand excluded by PLIPEDO.26: 6 residues within 4Å:- Chain B: Y.165, V.169, R.330, Y.422, Y.456
- Ligands: UDP.16
Ligand excluded by PLIPEDO.27: 4 residues within 4Å:- Chain B: Q.101, E.119, E.120
- Ligands: EDO.23
Ligand excluded by PLIPEDO.28: 4 residues within 4Å:- Chain B: F.69, S.70, T.212, F.213
Ligand excluded by PLIPEDO.29: 5 residues within 4Å:- Chain B: G.65, V.67, W.318, R.330
- Ligands: FDA.15
Ligand excluded by PLIPEDO.30: 6 residues within 4Å:- Chain B: W.181, L.182, G.183, P.487, D.488, N.491
Ligand excluded by PLIPEDO.38: 3 residues within 4Å:- Chain A: E.497
- Chain C: W.446, N.474
Ligand excluded by PLIPEDO.39: 6 residues within 4Å:- Chain C: Y.165, V.169, R.330, Y.422, Y.456
- Ligands: UDP.32
Ligand excluded by PLIPEDO.40: 7 residues within 4Å:- Chain C: V.67, F.69, R.94, N.460
- Ligands: FDA.31, UDP.32, EDO.43
Ligand excluded by PLIPEDO.41: 4 residues within 4Å:- Chain C: R.306, G.307, D.408, E.409
Ligand excluded by PLIPEDO.42: 5 residues within 4Å:- Chain C: I.68, F.69, S.70, T.212, F.213
Ligand excluded by PLIPEDO.43: 7 residues within 4Å:- Chain C: G.65, H.66, V.67, W.318, R.330
- Ligands: FDA.31, EDO.40
Ligand excluded by PLIPEDO.44: 8 residues within 4Å:- Chain C: Q.110, M.128, M.152, M.153, A.188, P.189, N.190, V.194
Ligand excluded by PLIPEDO.45: 3 residues within 4Å:- Chain C: A.204, G.205, W.207
Ligand excluded by PLIPEDO.46: 6 residues within 4Å:- Chain C: W.181, L.182, G.183, P.487, D.488, N.491
Ligand excluded by PLIPEDO.53: 3 residues within 4Å:- Chain B: E.497
- Chain D: W.446, N.474
Ligand excluded by PLIPEDO.54: 6 residues within 4Å:- Chain D: Y.165, V.169, R.330, Y.422, Y.456
- Ligands: UDP.48
Ligand excluded by PLIPEDO.55: 6 residues within 4Å:- Chain D: G.65, H.66, V.67, W.318, R.330
- Ligands: FDA.47
Ligand excluded by PLIPEDO.56: 8 residues within 4Å:- Chain D: Q.110, M.128, M.152, M.153, A.188, P.189, N.190, V.194
Ligand excluded by PLIPEDO.57: 6 residues within 4Å:- Chain D: W.181, L.182, G.183, P.487, D.488, N.491
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Da Fonseca, I. et al., Contributions of Unique Active Site Residues of Eukaryotic UDP-Galactopyranose Mutases to Substrate Recognition and Active Site Dynamics. Biochemistry (2014)
- Release Date
- 2014-12-03
- Peptides
- UDP-galactopyranose mutase: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.05 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x FDA: DIHYDROFLAVINE-ADENINE DINUCLEOTIDE(Non-covalent)
- 7 x UDP: URIDINE-5'-DIPHOSPHATE(Non-covalent)
- 18 x SO4: SULFATE ION(Non-functional Binders)
- 28 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Da Fonseca, I. et al., Contributions of Unique Active Site Residues of Eukaryotic UDP-Galactopyranose Mutases to Substrate Recognition and Active Site Dynamics. Biochemistry (2014)
- Release Date
- 2014-12-03
- Peptides
- UDP-galactopyranose mutase: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D